Evidence map›Paper›PMID 32754604›Full record

ArticleFrontiers in medicine2020

Histone Methylation Inhibitor DZNep Ameliorated the Renal Ischemia-Reperfusion Injury

Jiawei Li, Yue Qiu, Long Li, Jiyan Wang, Yin Celeste Cheuk, Ruirui Sang, Yichen Jia, Jina Wang, Yi Zhang, Ruiming Rong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The Role of Histone H3 Methylation in Acute Kidney Injury.Drug design, development and therapy · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Jiawei LiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yue QiuShanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Long LiDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jiyan WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yin Celeste CheukDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ruirui SangShanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Yichen JiaDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jina WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yi ZhangShanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Ruiming RongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNZhongshan Hospital · CNShanghai Institute of Organic Chemistry · CNShanghai Ninth People's Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal ischemia-reperfusion injury (IRI) after renal transplantation often leads to the loss of kidney graft function. However, there is still a lack of efficient regimens to prevent or alleviate renal IRI. Our study focused on the renoprotective effect of 3-Deazaneplanocin A (DZNep), which is a histone methylation inhibitor. We found that DZNep significantly alleviated renal IRI by suppressing nuclear factor kappa-B (NF-κB), thus inhibiting the expression of inflammatory factors in renal tubular epithelial cells

Indexed as

DZNepNF-κBrenal IRIT cellsTIM-1

Identifiers

PMID32754604
PMCPMC7365856
OpenAlexW3036784846

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.